Company
Every investor coverage indicates participated in a round Mesoblast raised.
Companies Mesoblast acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Silviu Itescu | Chief Executive | Biotech Dispatch, @AuManufacturing |
Stories naming Mesoblast. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Mesoblast's yearly report shows revenue leaping on first-year American sales of Ryoncil, losses narrowing, and a US$125 million debt refinancing, with its spinal disc trial fully recruited ahead of 2027 data.
Mesoblast has finished dosing all 350 patients in its phase 3 trial of rexlemestrocel-L for degenerative disc disease, with data due mid-2027 and a possible US biologics application to follow.
Mesoblast says the US FDA has confirmed its clinical data now supports refiling the remestemcel-L biologics application for pediatric patients, with resubmission planned next quarter; shares rose on the announcement.
Newsletter highlights Australian startup funding including Jet Zero, Kismet, VaultEscrow, Jupiter Ionics, ChronoForge, FLK it over, Anni, and Bae Juice, alongside M&A activity.
Also Early VC
AI search startup Marqo has landed a $12.5 million Series A and is relocating its headquarters to San Francisco, while LaunchVic statistics show Victoria's ecosystem grew in value despite a funding drop.
Roundup of manufacturing news: Namoi Cotton agrees a takeover scheme with Louis Dreyfus, Bio-Gene receives an R&D tax payment, SPEE3D and NIOA appoint executives, and Cicada opens workshop applications.